STAT3/STAT5 Dual Inhibitor, SH-4-54

Cell permeable: yes

Reversible: yes

Secondary Target
STAT5

Toxicity: Standard Handling (A)

A cell-permeable, salicyclic-to-benzoic acid-substituted BP-1-102 (Cat. no. 573132-M) analog that targets STAT3 and STAT5 with comparable affinity (k_off/k_on = K_D = 300 and 464 nM, respectively) and is 4-fold more potent in competing against phosphopeptide for binding to SH2 domain of STAT3 over STAT1 (K_i = 23.5 and 92.3 µM, respectively; [phosphopeptide] = 10 nM), exhibiting little potency against the kinase activity of upstream kinases (Akt1, Erk1, JAK1/2, c-Src) or the activation of 21 GPCRs, and displaying much reduced or no affinity toward other kinases in a 101-panel screen. Selectively inhibits cellular STAT3 Y705, but not S727, phosphorylation (0.5 to 5 µM) and is a more potent anticancer agent than BP-1-102 against gliobalstoma (GMB) patients-derived brain tumor stem cell (BTSC) cultures (IC₅₀ from 42 to 530 nM). Reported to penetrate blood-brain-barrier in mice (Conc in brain = 313 nM 30 min post 10 mg/kg i.p. dosing) and effectively inhibit BT73 glioma proliferation in xenografted murine brain via apoptosis induction (10 doses: 10 mg/kg i.p., 4 d on/ 3 d off) in vivo.

Haftchenary, S., et al. 2013. ACS Med. Chem. Lett.4, In press.

Packaged under inert gas

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany